Copanlisib (BAY80-6946)

DRUG9 trials

Sponsors

Bayer

Conditions

Advanced or Metastatic Solid TumorHealthy VolunteersLymphoma Non-HodgkinLymphoma, Mantle-CellLymphoma, Non-HodgkinMedical OncologyNeoplasmsNon Hodgkin Lymphoma

Phase 1

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

CompletedNCT01411410

Start: 2011-08-24End: 2015-06-29Updated: 2017-10-11

Copanlisib Mass Balance Study

CompletedNCT02119221

BayerHealthy Volunteers

Start: 2014-02-28End: 2014-10-31Updated: 2014-10-28

Copanlisib Pharmacodynamic Study

CompletedNCT02155582

BayerNon Hodgkin Lymphoma

Start: 2014-08-12End: 2017-03-16Updated: 2017-06-16

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

CompletedNCT02253420

BayerMedical Oncology

Start: 2014-10-08End: 2019-08-13Updated: 2020-12-14

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

CompletedNCT02342665

BayerLymphoma Non-Hodgkin

Start: 2015-04-21End: 2022-02-10Updated: 2023-01-20

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors

CompletedNCT03517956

BayerAdvanced or Metastatic Solid Tumor

Start: 2018-07-25End: 2021-02-01Updated: 2022-07-14

Phase 2

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

TerminatedNCT02455297

BayerLymphoma, Mantle-Cell

Start: 2015-08-24End: 2016-08-31Updated: 2017-10-02

Phase 3

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

TerminatedNCT02626455

BayerLymphoma, Non-Hodgkin

Start: 2016-01-06End: 2023-11-10Updated: 2024-12-11

Unknown Phase

A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

CompletedNCT05217914

BayerRelapsed or Refractory Indolent Non-Hodgkin Lymphoma

Start: 2022-07-01End: 2024-08-31Updated: 2024-10-24

Related Papers

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Blood Advances2024-07-2612 citations

PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB)

HemaSphere2022-06-01

Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.

2021-07-0211 citations

COPANLISIB IN COMBINATION WITH RITUXIMAB‐BENDAMUSTINE IN PATIENTS WITH RELAPSED‐REFRACTORY DLBCL: A MULTICENTRIC PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI

Hematological Oncology2021-06-012 citations

Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models

Experimental and Molecular Therapeutics2019-07-012 citations

Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models

Cancer Research2019-07-012 citations

EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB

Hematological Oncology2019-06-017 citations

PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors

Annals of Oncology2018-10-014 citations

Copanlisib monotherapy activity in relapsed or refractory indolent B-cell lymphoma: Combined analysis from phase I and II studies

Annals of Oncology2018-10-01

Effects of rifampin on the pharmacokinetics of copanlisib, a novel pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor in cancer patients.

Journal of Clinical Oncology2018-05-201 citations

PI3K Inhibition in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Oncology Times2018-02-09

PI3K Inhibitor Shows Promise for Patients With Relapsed/Refractory Disease

Oncology Times2017-10-31

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.

2017-09-01195 citations

SAFETY RUN‐IN OF COPANLISIB IN COMBINATION WITH RITUXIMAB PLUS BENDAMUSTINE IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA

Hematological Oncology2017-06-015 citations

INTEGRATED SAFETY DATA WITH COPANLISIB MONOTHERAPY FROM PHASE I AND II TRIALS IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN'S LYMPHOMA

Hematological Oncology2017-06-011 citations

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.

2016-12-0336 citations

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

2016-10-01181 citations

Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma

Blood2015-12-038 citations